Researchers at the University of Pittsburgh show that the simple difference between being fasted and being fed at the moment your immune system is activated leaves a durable, heritable stamp on your killer (CD8+) T cells. Fed-state T cells carry more mitochondria, burn more fuel, and produce more inflammatory cytokines — and they keep these advantages through weeks of division in vivo and in vitro. The active ingredient is not glucose or protein but triglyceride-rich chylomicrons (the lipid particles that flood your blood after a meal), which are taken up via the LDL receptor and used to switch on mTORC1, boosting protein translation. The headline practical payoff: CAR-T cells manufactured from a donor’s postprandial blood outperformed cells from the same donor’s fasted blood in mouse leukemia models.
It turns out your immune system may care whether you have eaten. In a paper published in Nature, a team led by Greg Delgoffe reports that the short-term nutritional state of the body — fasted versus fed — measurably reprograms T cells, the white blood cells that hunt viruses and tumors.
The group drew blood from healthy volunteers first after an overnight fast, then again several hours after a meal. T cells from the fed draw were metabolically supercharged: they took up more glucose, stored more lipid, carried more mitochondria, and released more of the cytokines that coordinate an immune attack. Crucially, these were the same people hours apart — so the change came from the meal, not from who they were.
The surprise is that the advantage stuck. Even after the cells were activated and forced to divide for a week in culture, or transferred into mice and expanded during a viral infection, the “fed” cells stayed ahead of their “fasted” counterparts. In mice, that head start persisted for months, out to at least 40 weeks. In other words, a transient nutritional signal was inherited by cells many generations removed from the original meal.
What carries the message? Not sugar, not protein, and not insulin. The team traced it to chylomicrons — the triglyceride-loaded particles the gut ships into the bloodstream after fatty food. Strip chylomicrons out of fed serum and the effect vanishes; add purified chylomicrons back to fasted cells and it returns. Inside the cell, chylomicron-derived cholesterol activates mTORC1, the master growth switch, ramping up the protein-building machinery so the cell is primed to explode into action the instant it meets its target.
The most eye-catching translation is for cancer immunotherapy. When the researchers built human CD19-targeted CAR-T cells from the same donor’s fasted versus fed blood, the postprandial product killed leukemia cells more efficiently and kept mice alive significantly longer. That hints at an almost embarrassingly cheap manufacturing tweak: collect the patient’s cells after a meal.
The caveats are real. This is young, healthy donors and young mice; nobody has yet shown that eating before a flu shot improves the flu shot. And there is an intriguing tension for the longevity field — the very pathway being switched on here, mTORC1, is the one that drugs like rapamycin deliberately switch off to extend healthspan. The authors show rapamycin abolishes the fed-state boost. Feast and famine, it seems, are both instructions the immune system reads closely.
Actionable Insights
Take-home messages, with magnitudes. Note the paper reports p-values and means +/- SEM but calculated no formal effect sizes, so the figures below are estimated from reported statistics and figure values.
- Vaccination/immune-challenge timing. In the model systems, being fed at the time of T-cell activation raised metabolic and effector readouts by roughly 1.3x to 2x (glucose uptake ~1.5x, spare respiratory capacity ~2x, double-cytokine-positive CD8+ cells ~1.3-1.6x). Whether timing a human vaccine to a postprandial, lipid-containing meal improves real antibody/T-cell responses is not tested — treat as a plausible, unproven hypothesis.
- If you take rapamycin. The paper shows in-vivo rapamycin (5 mg/kg during the feed window) cancels the postprandial priming. This supports the existing practice of spacing mTOR inhibition away from vaccination or acute immune challenges rather than dosing through them.
- Cell-therapy manufacturing. Postprandial CAR-T products showed higher cytotoxicity at every effector:target ratio (p = 0.0018 to 0.0070) and prolonged mouse survival (p = 0.0030). If you or a client is planning apheresis for adoptive cell therapy, fed-state collection is a low-cost variable worth raising with the treating team.
- What this does NOT license. This is not evidence that habitual fatty meals improve health or longevity. The signal is about T-cell state at the moment of activation, not chronic diet. Over-reading it as “eat more fat to boost immunity” is unsupported.
Context / Source
- Open Access Paper: Postprandial lipid metabolism durably enhances T cell immunity.
- Institution / Country: University of Pittsburgh and UPMC Hillman Cancer Center, Pittsburgh, PA, USA. Corresponding author Greg M. Delgoffe.
- Journal: Nature. Vol 654, 25 June 2026, pp. 1065-1075. DOI 10.1038/s41586-026-10432-8. Received 7 March 2025; accepted 19 March 2026; published online 29 April 2026.
- Impact evaluation: The impact score of this journal is 56.1 (2025 JCR, released June 2026), evaluated against a typical high-end range of 0-60+ for top general science, therefore this is an Elite impact journal.